In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quintiles' Internet Gambit

Executive Summary

Quintiles is investing heavily in building a platform of web-enabled technology tools for clinical development that it hopes will nudge Big Pharma towards wider adoption of that technology and foster the kind of strategic partnerships that many see as crucial to the future health of the CRO industry.However, despite a consensus that the Internet will eventually revolutionize the way that clinical trials are done, there's also agreement that wide-spread adoption of web-based studies is a ways off.One likely reason that drug companies have moved slowly in this area is that they've been bombarded with pitches from start-up technology companies, promising to transform the clinical study process, but seemingly lacking the infrastructure and financial strength to assure that they can follow through on those promises.Quintiles is looking to use the critical mass of its own resources, and those of its partner, WebMD, to develop the scaleable, supportable, and enterprise-wide solution that it believes Pharma is waiting for. But even for Quintiles, pouring money into web-enabled processes that are unlikely to yield any near-term rewards won't rekindle interest among investors already disappointed by the continuing industry slump.Nonetheless, Quintiles will need to bear the short-term stock hit if it is to reap the possible long-term benefit of moving away from the increasingly low-margin fee-for-service model to one based on more lucrative partnering agreements in which it works with Pharma to re-tool clinical development.

You may also be interested in...



Covance Weathers the CRO Storm

The CRO faces some long-term challenges. The most important of these may be that of adapting to a changing pharmaceutical landscape, in which the shrinking of the customer base caused by consolidation increases the importance of establishing solid relationships with the large pharma companies remaining. Covance has taken several significant steps to prepare itself for the future, including streamlining its organizational structure and adding to its technology platform. Indeed, Covance's management believes that creating a broad portfolio of service offerings will help it to build long-lasting relationships with its drug company clients. There is, however, a tension between Covance's desire for breadth in its offerings and establishing the specialization that can assure quality. In fact, many believe that a major barrier to building strategic CRO/Pharma partnerships is a perception that CROs can't be depended upon to produce high caliber work.One approach to addressing those concerns is through risk-sharing arrangements that offer CROs larger margins for a job well-done and penalizes them for poor performance. If the only way for CROs to ensure long-term stability is through long-term risk-sharing alliances with drug companies, Covance and its competitors will need to decide whether they can best win these deals with a one-stop shopping mall or with a high end boutique.

Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab

The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab. 

Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing

Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV001516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel